Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
Monitoring during the transition If you have diabetes or prediabetes, tracking your blood sugar alongside your urinary frequency provides valuable context
Additionally, you must also complete a full medical evaluation, including lab tests and a review of your current medical history
Like semaglutide, it activates GLP-1 receptors
Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption
To watch this and all of Joe-Gilboy PA-C's video lessons, you must be a member